Structure Therapeutics (GPCR) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- -$0.49
- Estimate
- -$0.38
- Surprise
- -29.3%
- Score today
- 4.6/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Structure Therapeutics (GPCR) reported a wider loss than forecast — adjusted EPS of -$0.49 against the -$0.38 estimate (a 29.3% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates GPCR Sell at 4.6/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate; this quarter's -29.3% surprise compares with a +29.4% four-quarter average. Next scheduled report: 2026-11-05.
What argues against it
- Concentration risk — Pipeline: aleniglipron
- DATA_ISSUE: analyst_target_implausible (raw $105.78 vs price $21.88 — ratio 4.8×). Rejected, falling back to technical TP.
- Quality below floor (1.6 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $21.88
- Price target
- $36.99
- Stop
- $20.90
- Upside to target
- +69.1%
Risk check: RSI 0 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-10-14 — shown for context, not personalized investment advice.
GPCR at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $1.59B
- P/E (fwd)
- -10.6
- 52-week range
- $22.15–$94.90
- Off 52-week high
- 76.9%
- RSI (14)
- 0
- Volume vs avg
- 1.04×
- Score today
- 4.6/10